Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo

Breast Cancer Research and Treatment

Volumn 128, Issue 1, 2011, Pages 69-78

  Chen, Yi ^a,b   Alvarez, Edwin A ^a   Azzam, Diana ^a,c   Wander, Seth A ^a,c   Guggisberg, Natalia ^a   Jordà, Mercè ^a,c   Ju, Zhenlin ^d   Hennessy, Bryan T ^d   Slingerland, Joyce M ^a,c  

^a UNIVERSITY OF MIAMI   (United States)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; Cell cycle; Fulvestrant; p27; Src inhibitor; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; FULVESTRANT; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN P27; PROTEIN TYROSINE KINASE; SARACATINIB; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIOXOLES; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; G1 PHASE; HUMANS; KI-67 ANTIGEN; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SRC-FAMILY KINASES; TAMOXIFEN; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959249550     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1024-7     Document Type: Article

References (40)

1. A Howell JF Robertson P Abram MR Lichinitser R Elledge E Bajetta T Watanabe C Morris A Webster I Dimery CK Osborne 2004 Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial J Clin Oncol 22 9 1605 1613 15117982 10.1200/JCO.2004.02.112 1:CAS:528:DC%2BD2cXpsVWmu7w%3D (Pubitemid 41079798)
2. S Chia W Gradishar L Mauriac J Bines F Amant M Federico L Fein G Romieu A Buzdar JF Robertson A Brufsky K Possinger P Rennie F Sapunar E Lowe M Piccart 2008 Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT J Clin Oncol 26 10 1664 1670 18316794 10.1200/JCO.2007.13. 5822 1:CAS:528:DC%2BD1cXltlWhsrg%3D
3. RL Sutherland MD Green RE Hall RR Reddel IW Taylor 1983 Tamoxifen induces accumulation of MCF7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle Eur J Cancer Clin Oncol 19 615 621 6683633 10.1016/0277-5379(83) 90177-3 1:CAS:528:DyaL3sXktlart74%3D (Pubitemid 13100370)
4. S Cariou JC Donovan WM Flanagan A Milic N Bhattacharya JM Slingerland 2000 Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells Proc Natl Acad Sci USA 97 16 9042 9046 10908655 10.1073/pnas.160016897 1:CAS:528:DC%2BD3cXls12lu7c%3D (Pubitemid 30626670)
5. CK Osborne DH Boldt GM Clark JM Trent 1983 Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase Cancer Res 43 3583 3585 6861130 1:CAS:528:DyaL3sXlsFant7o%3D (Pubitemid 13026612)
6. CKW Watts A Brady B Sarcevic A deFazio RL Sutherland 1996 Antiestrogens inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation Mol Endocrinol 9 1804 1813 10.1210/me.9.12.1804
7. RI Nicholson AB Francis RA McClelland DL Manning JMW Gee 1994 Pure anti-oestrogens (ICI 164384 and ICI 182780) and breast cancer: is the attainment of complete estrogen withdrawal worthwhile? Endocr Relat Cancer 3 1 13
8. IC Henderson AJ Patek 1998 The relationship between prognostic and predictive factors in the management of breast cancer Breast Cancer Res Treat 52 1-3 261 288 10066087 10.1023/A:1006141703224 1:STN:280:DyaK1M7mtl2ksg%3D%3D (Pubitemid 29056100)
9. Y Chen N Guggisberg M Jorda A Gonzalez-Angulo B Hennessy GB Mills CK Tan JM Slingerland 2009 Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors Clin Cancer Res 15 10 3396 3405 19451593 10.1158/1078-0432.CCR-08-3127 1:CAS:528:DC%2BD1MXmtVKmu7o%3D
10. A Migliaccio M DiDomenico C Castona A DeFalco P Bontempo E Nola F Auricchio 1996 Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol receptor complex in MCF-7 cells EMBO J 15 1292 1300 8635462 1:CAS:528:DyaK28XitFWjtLo%3D
11. P Collins C Webb 1999 Estrogen hits the surface Nat Med 5 10 1130 1131 10502813 10.1038/13453 1:CAS:528:DyaK1MXms1Wktr4%3D (Pubitemid 29474415)
12. G Castoria A Migliaccio A Bilancio M Di Domenico A de Falco M Lombardi R Fiorentino L Varricchio MV Barone F Auricchio 2001 PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells EMBO J 20 21 6050 6059 11689445 10.1093/emboj/20.21.6050 1:CAS:528:DC%2BD3MXovVSitLs%3D (Pubitemid 33049280)
13. A Migliaccio M Pagano F Auricchio 1993 Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells Oncogene 8 2183 2191 7687761 1:CAS:528:DyaK3sXmtVSrs7o%3D (Pubitemid 23226952)
14. A Migliaccio G Castoria M Di Domenico A de Falco A Bilancio M Lombardi MV Barone D Ametrano MS Zannini C Abbondanza F Auricchio 2000 Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation EMBO J 19 20 5406 5417 11032808 10.1093/emboj/19.20.5406 1:CAS:528:DC%2BD3cXotFKqtbo%3D
15. G Castoria M Lombardi MV Barone A Bilancio DM Di D Bottero F Vitale A Migliaccio F Auricchio 2003 Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action J Cell Biol 161 3 547 556 12743104 10.1083/jcb.200211099 1:CAS:528:DC%2BD3sXjvVeqsL0%3D (Pubitemid 36578579)
16. EA Musgrove RL Sutherland 1994 Cell cycle control by steroid hormones Semin Cancer Biol 5 5 381 389 7849266 1:CAS:528:DyaK2MXitFCmtLg%3D (Pubitemid 124006791)
17. AP Belsches-Jablonski JS Biscardi DR Peavy DA Tice DA Romney SJ Parsons 2001 Src family kinases and HER2 interactions in human breast cancer cell growth and survival Oncogene 20 12 1465 1475 11313890 10.1038/sj.onc.1204205 1:CAS:528:DC%2BD3MXis1Klsbc%3D (Pubitemid 32291197)
18. S Hiscox NJ Jordan C Smith M James L Morgan KM Taylor TP Green RI Nicholson 2008 Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells Breast Cancer Res Treat 115 1 57 67 18493848 10.1007/s10549-008-0058-6
19. I Chu J Sun A Arnaout H Kahn W Hanna S Narod P Sun CK Tan L Hengst J Slingerland 2007 p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2 Cell 128 2 281 294 17254967 10.1016/j.cell.2006.11.049 1:CAS:528:DC%2BD2sXhsVOqsr4%3D (Pubitemid 46123510)
20. M Grimmler Y Wang T Mund Z Cilensek EM Keidel MB Waddell H Jakel M Kullmann RW Kriwacki L Hengst 2007 Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases Cell 128 2 269 280 17254966 10.1016/j.cell.2006.11.047 1:CAS:528:DC%2BD2sXhsVOru7c%3D (Pubitemid 46123508)
21. KM Coleman CL Smith 2001 Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors Front Biosci 6 D1379 D1391 11578956 10.2741/Coleman 1:CAS:528: DC%2BD3MXnsFCgur0%3D
22. RX Song CJ Barnes ZG Zhang YD Bao R Kumar RJ Santen 2004 The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane Proc Natl Acad Sci USA 101 7 2076 2081 14764897 10.1073/pnas.0308334100 1:CAS:528:DC%2BD2cXhs1Srsr0%3D (Pubitemid 38229017)
23. PA Ple TP Green LF Hennequin J Curwen M Fennell J Allen C Lambert-Van Der Brempt G Costello 2004 Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src J Med Chem 47 4 871 887 14761189 10.1021/jm030317k 1:CAS:528: DC%2BD2cXksFCjtg%3D%3D (Pubitemid 38176790)
24. TP Green M Fennell R Whittaker J Curwen V Jacobs J Allen A Logie J Hargreaves DM Hickinson RW Wilkinson P Elvin B Boyer N Carragher PA Ple A Bermingham GA Holdgate WH Ward LF Hennequin BR Davies GF Costello 2009 Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 Mol Oncol 3 248 261 10.1016/j.molonc.2009.01.002 1:CAS:528:DC%2BC3cXjslKnsL0%3D
25. MH Herynk AR Beyer Y Cui H Weiss E Anderson TP Green SA Fuqua 2006 Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells Mol Cancer Ther 5 12 3023 3031 17172405 10.1158/1535-7163.MCT-06-0394 1:CAS:528:DC%2BD28Xhtlagsb3E (Pubitemid 46092043)
26. I Chu A Arnaout S Loiseau J Sun A Seth C McMahon K Chun B Hennessy GB Mills Z Nawaz JM Slingerland 2007 Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer J Clin Investig 117 8 2205 2215 17627304 10.1172/JCI21739 1:CAS:528:DC%2BD2sXoslOns7w%3D (Pubitemid 47219565)
27. C Catzavelos N Bhattacharya YC Ung JA Wilson L Roncari C Sandhu P Shaw H Yeger I Morava-Protzner L Kapusta E Franssen KI Pritchard JM Slingerland 1997 Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer Nat Med 3 2 227 230 9018244 10.1038/nm0297-227 1:CAS:528:DyaK2sXpsFWisA%3D%3D (Pubitemid 27064710)
28. R Tibes Y Qiu Y Lu B Hennessy M Andreeff GB Mills SM Kornblau 2006 Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells Mol Cancer Ther 5 10 2512 2521 17041095 10.1158/1535-7163.MCT-06-0334 1:CAS:528:DC%2BD28XhtVOmtbfI (Pubitemid 44650915)
29. BT Hennessy YL Lu E Poradosu QH Yu SX Yu H Hall MS Carey M Ravoori AM Gonzalez-Angulo R Birch IC Henderson V Kundra GB Mills 2007 Pharmacodynamic markers of perifosine efficacy Clin Cancer Res 13 24 7421 7431 18094426 10.1158/1078-0432.CCR-07-0760 1:CAS:528:DC%2BD2sXhsVCktr3K
30. RP Dings Y Yokoyama S Ramakrishnan AW Griffioen KH Mayo 2003 The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin Cancer Res 63 2 382 385 12543791 1:CAS:528:DC%2BD3sXnt1Krsw%3D%3D (Pubitemid 36152496)
31. J Hu X He KA Baggerly KR Coombes BTJ Hennessy GB Mills 2007 Non-parametric quantification of protein lysate arrays Bioinformatics 23 15 1986 1994 17599930 10.1093/bioinformatics/btm283 1:CAS:528:DC%2BD2sXpt1Crtbg%3D (Pubitemid 47299840)
32. EV Jensen VC Jordan 2003 The estrogen receptor: a model for molecular medicine Clin Cancer Res 9 6 1980 1989 12796359 1:CAS:528:DC%2BD3sXksVWqtb8%3D (Pubitemid 36687616)
33. S Ali RC Coombes 2002 Endocrine-responsive breast cancer and strategies for combating resistance Nat Rev Cancer 2 2 101 112 12635173 10.1038/nrc721 (Pubitemid 37328797)
34. R Clarke F Leonessa JN Welch TC Skaar 2001 Cellular and molecular pharmacology of antiestrogen action and resistance Pharmacol Rev 53 1 25 71 11171938 1:CAS:528:DC%2BD3MXhsFWqtLY%3D (Pubitemid 32173107)
35. SR Johnston LA Martin A Leary J Head M Dowsett 2007 Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer J Steroid Biochem Mol Biol 106 1-5 180 186 17624764 10.1016/j.jsbmb.2007.05.019 1:CAS:528:DC%2BD2sXhtVWitbjI (Pubitemid 47362648)
36. SR Johnston LA Martin J Head I Smith M Dowsett 2005 Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance J Steroid Biochem Mol Biol 95 1-5 173 181 15996863 10.1016/j.jsbmb.2005.04.004 1:CAS:528:DC%2BD2MXntVOhtbs%3D (Pubitemid 41137308)
37. I Chu K Blackwell S Chen J Slingerland 2005 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer Cancer Res 65 1 18 25 15665275 10.1158/0008-5472.CAN-04-3270 1:CAS:528:DC%2BD2MXhvFahtw%3D%3D (Pubitemid 40827342)
38. MD Planas-Silva RA Weinberg 1997 Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution Mol Cell Biol 17 7 4059 4069 9199341 1:CAS:528:DyaK2sXktFOhtbo%3D (Pubitemid 27281882)
39. J Foster J Wimalasen 1996 Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells Mol Endocrinol 10 488 496 8732680 10.1210/me.10.5.488 1:CAS:528:DyaK28Xislyis7Y%3D (Pubitemid 26142575)
40. OWJ Prall B Sarcevic EA Musgrove CKW Watts RL Sutherland 1997 Estrogen induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin dependent inhibitor association with cyclin E-Cdk2 J Biol Chem 272 10882 10894 9099745 10.1074/jbc.272.16.10882 1:CAS:528:DyaK2sXivVSgsrw%3D (Pubitemid 27181106)